Back to top
more

Avadel Pharmaceuticals (AVDL)

(Delayed Data from NSDQ)

$18.82 USD

18.82
874,892

+0.52 (2.84%)

Updated May 3, 2024 04:00 PM ET

After-Market: $18.81 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AVDL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Avadel Pharmaceuticals PLC. [AVDL]

Reports for Purchase

Showing records 21 - 40 ( 44 total )

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 21

05/17/2021

Company Report

Pages: 6

Jazz Suit Not a Surprise; Doesn’t Trigger FDA Delay; Case Unlikely to Merit a Preliminary Injunction; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 22

05/11/2021

Company Report

Pages: 7

Nearing Mid-Cycle Review With No Indication of IPRelated FT218 Approval Impediments; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 23

03/10/2021

Company Report

Pages: 8

Stock Doesn’t Reflect Incremental De-Risking of IP Certification Issue; Raise to $17 on Better Narcolepsy Market Pricing

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 24

11/10/2020

Company Report

Pages: 8

3Q20: Year-End FT218 Filing Plan Confirmed; Fears of Approval Roadblocks Overblown; Strong Buy Here

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 25

08/11/2020

Company Report

Pages: 8

2Q20: We Project FT218 NDA Around Year-End; Well-Funded and Undervalued; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 26

07/08/2020

Company Report

Pages: 6

Hospital Portfolio Sold as Laser focus is on FT218; Reiterate Buy and $15 Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 27

06/30/2020

Company Report

Pages: 28

We initiate coverage with a Buy rating and $15 price target

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 75.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 28

05/02/2018

Company Report

Pages: 4

Dropping Coverage due to reallocate our research resources

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 29

01/03/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 30

01/03/2018

Company Report

Pages: 11

Model Updated Post Guidance

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 31

11/14/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 32

11/13/2017

Company Report

Pages: 4

Encouraging Noctiva Analyst Day

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 33

11/09/2017

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 34

11/08/2017

Company Report

Pages: 10

3Q17 Recap - In-Line Quarter; Focus Shifts to Noctiva

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 35

10/09/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 36

10/06/2017

Company Report

Pages: 4

Meetings with Management

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 37

09/08/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 38

09/08/2017

Company Report

Pages: 6

Neutral on Noctiva; Positive on Sodium Oxybate and Éclat

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 39

08/09/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Avadel Pharmaceuticals PLC.

Industry: Medical - Drugs

Record: 40

08/09/2017

Company Report

Pages: 10

2Q17 Recap - No Major Surprises

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party